Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06079281 · ClinicalTrials.gov registry record · Phase 3

Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa

A Phase 3 study of Hypophosphatasia, sponsored by Alexion Pharmaceuticals.

Active
Registry status
Phase 3
Development phase
124
Enrollment target
20
Study locations

NCT06079281 is a Phase 3 study of Hypophosphatasia that is active but no longer recruiting, run by Alexion Pharmaceuticals. The registered enrollment target is 124 participants, above the 63-participant average among 6 other Hypophosphatasia trials with a reported enrollment target (97% higher). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06079281, a Phase 3 study of Hypophosphatasia, is active but no longer recruiting, sponsored by Alexion Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
124 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of this study is to assess the efficacy of ALXN1850 versus placebo on functional outcomes in adolescent and adult participants with HPP who have not previously been treated with asfotase alfa.

Conditions Studied

Hypophosphatasia

Interventions

  • DRUG Placebo
  • DRUG ALXN1850

Study Locations (20)

Other

  • Research Site - Ciudad de Buenos Aires
  • Research Site - Clayton
  • Research Site - Herston
  • Research Site - Parkville
  • Research Site - St Leonards
  • Research Site - Belo Horizonte
  • Research Site - Brasília
  • Research Site - Recife
  • Research Site - Salvador
  • Research Site - São Paulo
  • Research Site - São Paulo

Alberta

  • Research Site - Calgary
  • Research Site - Edmonton

Indiana

  • Research Site - Indianapolis

New York

  • Research Site - Garden City

North Carolina

  • Research Site - Durham

Ohio

  • Research Site - Columbus

Tennessee

  • Research Site - Nashville

Manitoba

  • Research Site - Winnepeg

Trial Details

FieldValue
Enrollment Target 124 participants
Start Date 2024-01-03
Est. Completion 2028-03-29
Phase Phase 3

Sponsor

Alexion Pharmaceuticals

162 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06079281

The ClinicalTrials.gov registry entry for NCT06079281 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 63-participant average among 6 other Hypophosphatasia trials with a reported enrollment target (97% higher). The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hypophosphatasia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06079281 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Alberta, Indiana.

Frequently Asked Questions

What is clinical trial NCT06079281 about?

NCT06079281 is a clinical study titled "Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa". The primary objective of this study is to assess the efficacy of ALXN1850 versus placebo on functional outcomes in adolescent and adult participants with HPP who have not previously been treated with asfotase alfa.

What is the current status of trial NCT06079281?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 124 participants. The study started on 2024-01-03. Estimated completion is 2028-03-29.

What conditions does trial NCT06079281 study?

This clinical trial studies the following conditions: Hypophosphatasia.

What interventions are being tested in trial NCT06079281?

The interventions under investigation include: Placebo (DRUG), ALXN1850 (DRUG).

Who is sponsoring clinical trial NCT06079281?

This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06079281 being conducted?

This trial has 20 study locations across Indiana, New York, North Carolina, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hypophosphatasia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hypophosphatasia

All registered trials for this condition

Indiana

All trials with a study site in Indiana

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.